參考文獻 |
[1]P. Krugman, "Pride, prejudice, insurance," New York Times, 2005.
[2]Y. T. Chang, C. Y. Hwang, Y. J. Chen, M. W. Lin, T. J. Chen, S. Y. Chu, et al., "Prevalence of Atopic Dermatitis, Allergic Rhinitis and Asthma in Taiwan: A National Study 2000 to 2007," Acta Dermato Venereologica, vol. 90, pp. 589-594, 2010.
[3]H.-C. Lin, I. J. Chen, Y.-H. Chen, H.-C. Lee, and F.-J. Wu, "Maternal schizophrenia and pregnancy outcome: Does the use of antipsychotics make a difference?," Schizophrenia Research, vol. 116, pp. 55-60, 2010.
[4]T. M. Doherty, Y.-C. Hsin, L.-Z. Zhuang, K.-W. Yeh, C.-W. Chang, J.-T. Horng, et al., "Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan," Plos One, vol. 10, p. e0128768, 2015.
[5]"Correction: Effects of Statins on Incident Dementia in Patients with Type 2 DM: A Population-Based Retrospective Cohort Study in Taiwan," PLoS ONE, vol. 9, p. e100019, 2014.
[6]K.-W. Yeh, C.-H. Yu, P.-C. Chan, J.-T. Horng, and J.-L. Huang, "Burden of systemic lupus erythematosus in Taiwan: a population-based survey," Rheumatology International, vol. 33, pp. 1805-1811, 2013.
[7]M. A. Yıldırım, K.-I. Goh, M. E. Cusick, A.-L. Barabási, and M. Vidal, "Drug—target network," Nature Biotechnology, vol. 25, pp. 1119-1126, 2007.
[8]I. K. Jordan, G. Hu, and P. Agarwal, "Human Disease-Drug Network Based on Genomic Expression Profiles," PLoS ONE, vol. 4, p. e6536, 2009.
[9]"http://nhird.nhri.org.tw/en/."
[10]M. o. H. a. W. National Health Insurance Administration, Taiwan, "Universal Health Coverage in Taiwan," 2016.
[11]A.-L. Barabási, N. Gulbahce, and J. Loscalzo, "Network medicine: a network-based approach to human disease," Nature Reviews Genetics, vol. 12, pp. 56-68, 2011.
[12]J. P. D.-S. Lee, K. A. Kay, N. A. Christakis, Z. N. Oltvai and A.-L. Barabási, "The implications of human metabolic network topology for disease comorbidity," vol. 105, 2008.
[13]P.-J. Chang, "Construction of an interactive and visual system: combine disorders with climate changes and prescribing drugs effect into disease network," 2016.
[14]C. J. Mann, "Observational research methods. Research design II: cohort, cross sectional, and case-control studies," Emergency Medicine Journal, vol. 20, pp. 54-60, 2003.
[15]S. Rose and M. J. van der Laan, "Why Match? Investigating Matched Case-Control Study Designs with Causal Effect Estimation," The International Journal of Biostatistics, vol. 5, 2009.
[16]R. Baughman, A. Teirstein, M. Judson, M. Rossman, H. Yeager, E. Bresnitz, et al., "Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis," American Journal of Respiratory and Critical Care Medicine, vol. 164, pp. 1885-1889, 2001.
[17]S. Yusuf, S. Hawken, S. Ôunpuu, L. Bautista, M. G. Franzosi, P. Commerford, et al., "Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study," The Lancet, vol. 366, pp. 1640-1649, 2005.
[18]S. Roizenblatt, H. Moldofsky, A. A. Benedito-Silva, and S. Tufik, "Alpha sleep characteristics in fibromyalgia," Arthritis & Rheumatism, vol. 44, pp. 222-230, 2001.
[19]J. M. Monti and D. Monti, "Sleep disturbance in generalized anxiety disorder and its treatment," Sleep Medicine Reviews, vol. 4, pp. 263-276, 2000.
[20]H. P. Lavie P, Hoffstein V, "Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study.," vol. 320, pp. 479-482, 2000.
[21]W. H. Organization, "http://www.who.int/mediacentre/factsheets/fs138/en/."
[22]A. Imagawa and T. Hanafusa, "Pathogenesis of Fulminant Type 1 Diabetes," The Review of Diabetic Studies, vol. 3, pp. 169-169, 2006.
[23]S. D. Wacholder S, McLaughlin JK, Mandel JS., "Selection of controls in case-control studies. I. Principles.," vol. 135, pp. 1019-1028, 1992.
[24]S. D. Wacholder S, McLaughlin JK, Mandel JS., "Selection of controls in case-control studies. II. Types of controls.," vol. 135, pp. 1029-1041, 1992.
[25]S. D. Wacholder S, McLaughlin JK, Mandel JS., "Selection of controls in case-control studies. III. Design options.," vol. 135, pp. 1042-1050, 1992.
[26]B. M. Y. Cheung and C. Li, "Diabetes and Hypertension: Is There a Common Metabolic Pathway?," Current Atherosclerosis Reports, vol. 14, pp. 160-166, 2012.
[27]H. Z. Hamdan, E. Kubbara, A. M. Adam, O. S. Hassan, S. O. Suliman, and I. Adam, "Urinary tract infections and antimicrobial sensitivity among diabetic patients at Khartoum, Sudan," Annals of Clinical Microbiology and Antimicrobials, vol. 14, 2015.
[28]D. K. Ledford and R. F. Lockey, "Asthma and comorbidities," Current Opinion in Allergy and Clinical Immunology, vol. 13, pp. 78-86, 2013.
[29]W. W. Busse, R. F. Lemanske, and J. E. Gern, "Role of viral respiratory infections in asthma and asthma exacerbations," The Lancet, vol. 376, pp. 826-834, 2010.
[30]J. Corren, "Allergic rhinitis and asthma: How important is the link?," Journal of Allergy and Clinical Immunology, vol. 99, pp. S781-S786, 1997. |